Latest revenue
$78.4M
as of 2026-02-28
Latest net income
$-8.1M
as of 2026-02-28
Net margin
-10.3%
as of 2026-02-28
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ANGO is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $492.9M
- Enterprise value
- $480.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.84×
- Dividend yield
- 0.0%
- 52-wk high
- $13.99
- 52-wk low
- $8.36
- Beta
- —
- Shares out
- 41.3M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. OVERVIEW AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance. HISTORY AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out…
AI summary unavailable — showing raw filing excerpt
Generated from ANGO's filing dated 2025-07-18
Key risks
Item 1A. Risk Factors. In addition to the other information contained in this Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission, the following risk factors should be considered carefully by investors in evaluating our business. Our financial and operating results are subject to a number of risks and uncertainties, including those set forth below, many of which are not within our control. Our business, financial condition, results of operations and/or liquidity could be materially and adversely affected by any of these risks or by additional risks not presently known to us or that we currently deem immaterial. RISKS RELATED TO OUR BUSINESS AND…
AI summary unavailable — showing raw filing excerpt
Generated from ANGO's filing dated 2025-07-18
Profitability
Gross margin
53.9%
5.9%Operating margin
-13.7%
78.4%Net margin
-11.6%
80.8%Return on equity
-18.6%
79.3%Return on assets
-12.1%
79.1%Leverage
Debt / equity
0.53×
2.6%Long-term debt / equity
0.00×
100.0%Debt / assets
34.7%
1.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-02-28 | $78.4M | +8.9% | $-8.1M | -83.4% | -10.3% |
Q4 2025 2025-11-30 | $79.4M | +9.0% | $-6.3M | +40.9% | -8.0% |
Q3 2025 2025-08-31 | $75.7M | +12.2% | $-10.9M | +14.8% | -14.4% |
Q2 2025 2025-05-31 | $80.2M | +12.9% | $-6.0M | +92.1% | -7.5% |
Q1 2025 2025-02-28 | $72.0M | -4.2% | $-4.4M | +97.4% | -6.1% |
Q4 2024 2024-11-30 | $72.8M | -7.9% | $-10.7M | -163.8% | -14.7% |
Q3 2024 2024-08-31 | $67.5M | -14.2% | $-12.8M | -127.9% | -19.0% |
Q2 2024 2024-05-31 | $71.0M | — | $-76.2M | — | -107.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on ANGO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$239.5K
Insider selling
$0
Net activity
+$239.5K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ANGO
Institutional value
$206.0M
Total shares held
18.7M
Distinct holders
78
-87 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.7M | $41.9M | -174.6K (-4.5%) | Trimmed |
| 2 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 2.5M | $27.9M | -51.2K (-2.0%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $19.6M | — | New |
| 4 | ROYCE & ASSOCIATES LP | 1.5M | $17.4M | +261.5K (+20.6%) | Added |
| 5 | WEBER CAPITAL MANAGEMENT LLC /ADV | 1.4M | $15.6M | -27.0K (-1.9%) | Trimmed |
| 6 | Bastion Asset Management Inc. | 1.3M | $14.1M | +194.8K (+17.4%) | Added |
| 7 | Nuveen, LLC | 1.2M | $13.8M | -78.9K (-6.1%) | Trimmed |
| 8 | DIMENSIONAL FUND ADVISORS LP | 948.8K | $10.8M | +32.5K (+3.5%) | Added |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 436.5K | $5.0M | — | New |
| 10 | UBS Group AG | 391.3K | $4.4M | -338.8K (-46.4%) | Trimmed |
| 11 | Phocas Financial Corp. | 308.1K | $3.5M | -904.4K (-74.6%) | Trimmed |
| 12 | First Eagle Investment Management, LLC | 275.7K | $3.1M | +8.0K (+3.0%) | Added |
| 13 | VANGUARD FIDUCIARY TRUST CO | 273.7K | $3.1M | — | New |
| 14 | Connor, Clark & Lunn Investment Management Ltd. | 256.4K | $2.9M | -141.8K (-35.6%) | Trimmed |
| 15 | SEI INVESTMENTS CO | 212.7K | $2.4M | -9.4K (-4.2%) | Trimmed |
| 16 | KENNEDY CAPITAL MANAGEMENT LLC | 196.8K | $2.2M | +3.5K (+1.8%) | Added |
| 17 | Orion Porfolio Solutions, LLC | 130.0K | $1.5M | -11.8K (-8.3%) | Trimmed |
| 18 | WHITE PINE CAPITAL LLC | 124.6K | $1.4M | -25.9K (-17.2%) | Trimmed |
| 19 | Bank of New York Mellon Corp | 118.7K | $1.3M | -477 (-0.4%) | Trimmed |
| 20 | Invesco Ltd. | 109.8K | $1.2M | -4.7K (-4.1%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANGO's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.